Does Blue Cross Blue Shield of North Carolina Cover Ozempic?

What Ozempic Is and Why the Indication Matters for Coverage

Ozempic is a once-weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist containing semaglutide. The FDA approved it on December 5, 2017, specifically for glycemic control in adults with type 2 diabetes mellitus, and later added a cardiovascular risk-reduction indication for adults with type 2 diabetes and established cardiovascular disease based on the SUSTAIN-6 trial results. [1]

The indication on the label matters enormously for insurance coverage. BCBSNC, like most large commercial insurers, bases its coverage criteria on FDA-approved indications. A prescription written for weight loss alone, without a documented type 2 diabetes diagnosis, will almost certainly be denied under Ozempic's HCPCS/NDC code. Wegovy (semaglutide 2.4 mg) carries a separate FDA approval for chronic weight management and sits on a different formulary pathway entirely. [2]

The SUSTAIN-6 Trial and Why Physicians Cite It

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced the composite of major adverse cardiovascular events by 26% versus placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority) in patients with type 2 diabetes at high cardiovascular risk. [1] This cardiovascular outcome data strengthened payer confidence in coverage for the diabetic population, but it did not extend coverage to patients using the drug purely for weight management.

HbA1c Thresholds Insurers Typically Require

BCBSNC prior authorization criteria for Ozempic generally require documentation that the member has a confirmed type 2 diabetes diagnosis and an HbA1c of 7.0% or higher, or that the prescriber documents inadequate glycemic control on at least one prior oral antidiabetic agent. The American Diabetes Association's 2024 Standards of Care recommend initiating GLP-1 receptor agonists in patients with type 2 diabetes and HbA1c above target despite lifestyle modification, particularly when cardiovascular or renal comorbidities exist. [3]

How BCBSNC Formularies Classify Ozempic

BCBSNC operates multiple plan types: ACA Marketplace individual and family plans, fully insured employer group plans, self-funded employer plans administered by BCBSNC, and the North Carolina State Health Plan for teachers and state employees. Each of these may use a different formulary.

Commercial Individual and Family Plans

On most BCBSNC ACA Marketplace formularies, Ozempic falls in Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays commonly run $60, $100 per 30-day fill before the deductible is met, and $25, $60 after. Tier 4 cost-sharing can reach $150 or more per fill pre-deductible. The exact tier depends on the specific plan year and whether the member selected a Blue Value, Blue Select, or Blue Advantage plan.

Employer Group Plans

Fully insured employer group plans follow a BCBSNC-designed formulary, but self-funded employer plans set their own benefit structures. A self-funded employer may explicitly exclude GLP-1 agonists from coverage or impose step-therapy requirements mandating a trial of metformin plus one additional oral agent before Ozempic is authorized. Step therapy is now standard practice across most large pharmacy benefit managers. [4]

North Carolina State Health Plan

The NC State Health Plan (administered by BCBSNC for roughly 750,000 state employees and retirees) has historically placed Ozempic on a tier requiring prior authorization with documented type 2 diabetes. The plan's 2024 benefit documents confirm prior authorization as a prerequisite, and the plan has not uniformly covered GLP-1 medications for weight management purposes under Ozempic's NDC codes.

Prior Authorization: What Your Doctor Must Submit

Prior authorization (PA) is a written approval process where your prescribing physician submits clinical documentation to BCBSNC before the pharmacy will dispense Ozempic at the plan's covered rate.

Required Documentation Checklist

BCBSNC PA requests for Ozempic typically require:

• A confirmed ICD-10 code for type 2 diabetes mellitus (E11.xx) in the patient's chart
• Most recent HbA1c result (usually within the past 6 months)
• Documentation of at least one prior antidiabetic medication trial, commonly metformin (unless contraindicated by an eGFR <30 mL/min/1.73m² or gastrointestinal intolerance)
• Prescriber's DEA number and NPI
• Clinical notes supporting medical necessity

The FDA's prescribing information for Ozempic specifies that the drug is indicated as an adjunct to diet and exercise, so the PA form often asks whether lifestyle modification has been documented. [2]

How Long PA Approval Takes

Standard PA decisions from BCBSNC typically take 3 to 5 business days for non-urgent requests. Urgent requests submitted with documented clinical necessity should receive a response within 72 hours under North Carolina insurance regulations. If your prescriber submits an urgent PA and BCBSNC does not respond within 72 hours, you have grounds to escalate to the NC Department of Insurance.

Step Therapy and Fail-First Requirements

Many BCBSNC plans require a documented trial of metformin for at least 90 days before approving Ozempic. If metformin is contraindicated, the PA form must include the contraindication code and clinical rationale. Some plans also require a trial of a sulfonylurea or DPP-4 inhibitor before escalating to a GLP-1 agonist. The American Association of Clinical Endocrinology (AACE) 2023 guidelines do recommend GLP-1 receptor agonists earlier in the treatment algorithm for patients with obesity and type 2 diabetes, particularly those with cardiovascular risk. [5]

What Happens If BCBSNC Denies Your Ozempic Claim

A denial is not final. North Carolina law and federal ACA regulations give you the right to appeal.

Internal Appeal

Submit a written internal appeal within 180 days of the denial notice. Your prescriber should attach a letter of medical necessity citing your HbA1c, cardiovascular risk factors, and the relevant clinical trial data. Including a reference to SUSTAIN-6 (N=3,297, 26% relative risk reduction in MACE) [1] or the LEADER trial data for the drug class [6] can strengthen the clinical argument.

External Review

If the internal appeal fails, North Carolina members can request an external independent medical review through the NC Department of Insurance. The reviewer is a board-certified clinician unaffiliated with BCBSNC. Studies published in Health Affairs found that patients who pursue external appeals win approximately 40% of the time for prescription drug denials.

Expedited Appeals for Urgent Cases

If a denial poses an imminent risk to your health, request an expedited appeal. BCBSNC must respond within 72 hours. An endocrinologist's documentation stating that delay will result in serious deterioration of your condition qualifies most cases for expedited review.

Cost Without Coverage and Savings Options

Without insurance coverage, Ozempic's list price is approximately $935, $1,000 per 30-day supply (as of early 2025). That figure is prohibitive for most patients, but several options reduce the cost.

Novo Nordisk's Patient Assistance Programs

Novo Nordisk operates two programs:

1. The Ozempic Savings Card: Commercially insured patients who meet eligibility criteria may pay as little as $25 per 1-month, 2-month, or 3-month supply, up to a maximum savings of $150 per fill. This card does not apply to Medicare or Medicaid beneficiaries. [7]
2. The Patient Assistance Program (PAP): Uninsured or underinsured patients with household income at or below 400% of the federal poverty level may receive Ozempic at no cost through Novo Nordisk's NovoCare program.

GoodRx and Mark Cuban's Cost Plus Drugs

GoodRx coupons for Ozempic can reduce the cash price at certain North Carolina pharmacies to $850, $900, modest savings off list price, but still significant. Cost Plus Drugs does not currently carry brand-name Ozempic because it is patent-protected and not available as a generic.

Compounded Semaglutide: A Separate Regulatory Category

During periods when Ozempic or Wegovy appeared on the FDA drug shortage list, compounding pharmacies legally produced semaglutide preparations. The FDA removed semaglutide from the shortage list for most formulations in 2024, which triggered enforcement action against compounders. [8] Compounded semaglutide is not FDA-approved, carries no equivalence guarantee to brand-name Ozempic, and BCBSNC does not cover it. Patients should verify with the FDA shortage database before pursuing a compounded product.

Ozempic vs. Wegovy: Understanding the Coverage Split

This distinction causes more confusion than almost any other insurance issue in GLP-1 therapy. Both drugs contain semaglutide. The difference is the approved dose and the approved indication.

FDA-Approved Indications Side by Side

Ozempic (semaglutide 0.25 mg, 0.5 mg, 1 mg, 2 mg): Approved for type 2 diabetes glycemic control and cardiovascular risk reduction in adults with type 2 diabetes plus established cardiovascular disease. [2]

Wegovy (semaglutide 2.4 mg): Approved for chronic weight management in adults with a BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity. The SELECT trial (N=17,604) showed Wegovy reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease but without diabetes, a finding that has broadened payer interest in covering Wegovy specifically. [9]

Why Prescribing Ozempic Off-Label for Weight Loss Triggers Denials

Prescribing Ozempic for weight loss in a patient without type 2 diabetes is off-label use. BCBSNC, like most commercial insurers, excludes off-label use unless the prescriber can demonstrate published evidence in one of the recognized drug compendia (Micromedex, AHFS, Clinical Pharmacology). Off-label GLP-1 prescriptions for obesity without diabetes are routinely denied under Ozempic's NDC code. The correct drug for an insured weight-loss indication is Wegovy, and even Wegovy coverage requires a separate PA process.

The HealthRX Coverage Decision Framework below synthesizes the approval pathways for North Carolina BCBSNC members seeking GLP-1 therapy. Use this before calling your insurer.

HealthRX GLP-1 Coverage Decision Framework for BCBSNC Members

| Your Situation | Drug to Request | Likely Formulary Path | |---|---|---| | Type 2 diabetes, HbA1c >7%, tried metformin | Ozempic | PA required; approval likely with documentation | | Type 2 diabetes + established CVD | Ozempic | PA required; SUSTAIN-6 data supports medical necessity letter | | Obesity (BMI >30), no diabetes | Wegovy | Separate PA; check if your plan includes weight-management benefit | | Obesity (BMI 27 to 29.9) + hypertension or dyslipidemia, no diabetes | Wegovy | PA required; SELECT trial data useful in appeal | | No diabetes, BMI <27 | Neither drug covered by BCBSNC | Cash pay or manufacturer PAP only |

What Endocrinologists and Guideline Bodies Say

The Endocrine Society's 2023 clinical practice guidelines for pharmacological management of obesity state that GLP-1 receptor agonists are first-line pharmacotherapy for adults with a BMI of 30 or higher or a BMI of 27 or higher with comorbidities, when lifestyle intervention alone has not achieved adequate weight loss. [10] That recommendation covers Wegovy, not Ozempic, but it gives prescribers a strong guideline citation for Wegovy PA requests.

For type 2 diabetes specifically, the American Diabetes Association's 2024 Standards of Care note: "For patients with type 2 diabetes who have established cardiovascular disease or indicators of high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c." [3] That language from a named guideline document can be quoted verbatim in a PA letter or appeal to BCBSNC.

The AACE/ACE Comprehensive Diabetes Management Algorithm also places GLP-1 receptor agonists in the preferred agent category when HbA1c is more than 1.5% above target or when obesity is present alongside type 2 diabetes. [5]

Practical Steps for North Carolina Patients Right Now

Getting coverage approved requires coordinated action between you and your prescribing physician. The sequence that works most reliably involves confirming your current BCBSNC plan's specific formulary on the BCBSNC member portal (bcbsnc.com), calling the pharmacy benefits number on your insurance card to verify whether Ozempic requires PA under your specific plan ID, and then asking your prescriber's office to initiate the PA before the prescription is sent to the pharmacy.

Submitting the PA after the pharmacy has already run the claim and received a rejection creates delays because the pharmacy system registers a denial that must be reversed once PA is approved. Starting the PA first saves 7 to 10 days in most cases.

If your employer offers a self-funded plan and GLP-1 medications are excluded entirely from the formulary, a PA will not solve the problem. In that scenario, the appropriate path is to ask your HR department whether the plan includes an exception process, or to purchase the Novo Nordisk savings card for commercial patients and pay out-of-pocket with the discount applied.

North Carolina has not enacted a state mandate requiring commercial insurers to cover GLP-1 medications for obesity as of January 2025. Legislative proposals have been introduced in other states, and the field may shift in coming benefit years, but as of this writing there is no NC-specific statute compelling BCBSNC to cover Ozempic or Wegovy for weight management.